The Reg A+ landscape is complex, with businesses clamoring to participate from its potential. But fool biotech companies is it all promising figures? As the framework offers a innovative pathway for capital procurement, there are concerns that aspiring participants should be aware of. Firstly, the regulatory requirements can be complex, demanding